Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

HIV-2: A summary of present standard of care and treatment options for HIV-2 infected individuals living in Western Europe.

Berzow D, Descamps D, Obermeier M, Charpentier C, Kaiser R, Guertler L, Eberle J, Wensing A, Sierra S, Ruelle J, Gomes P, Mansinho K, Taylor N, Jensen B, Döring M, Stürmer M, Rockstroh J, Camacho R.

Clin Infect Dis. 2020 Mar 30. pii: ciaa275. doi: 10.1093/cid/ciaa275. [Epub ahead of print]

PMID:
32227124
2.

Clinical and virological data of the first cases of COVID-19 in Europe: a case series.

Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y.

Lancet Infect Dis. 2020 Mar 27. pii: S1473-3099(20)30200-0. doi: 10.1016/S1473-3099(20)30200-0. [Epub ahead of print]

PMID:
32224310
3.

Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients.

Marcelin AG, Charpentier C, Jary A, Perrier M, Margot N, Callebaut C, Calvez V, Descamps D.

J Antimicrob Chemother. 2020 Mar 10. pii: dkaa060. doi: 10.1093/jac/dkaa060. [Epub ahead of print]

PMID:
32154864
4.

Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V; ANRS 167 LAMIDOL Study Group .

J Antimicrob Chemother. 2020 Feb 24. pii: dkaa035. doi: 10.1093/jac/dkaa035. [Epub ahead of print]

PMID:
32091102
5.

M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.

Jary A, Marcelin AG, Charpentier C, Wirden M, Lê MP, Peytavin G, Descamps D, Calvez V.

J Antimicrob Chemother. 2020 Feb 17. pii: dkaa019. doi: 10.1093/jac/dkaa019. [Epub ahead of print]

PMID:
32065630
6.

Phylogenetic investigation of HCV-4d epidemic in Paris MSM HIV population reveals a still active outbreak and a strong link to the Netherlands.

Visseaux B, Hué S, Le Hingrat Q, Salmona M, Lebourgeois S, Delaugerre C, Descamps D, Chaix ML, Ghosn J.

Clin Microbiol Infect. 2020 Feb 6. pii: S1198-743X(20)30061-6. doi: 10.1016/j.cmi.2020.01.034. [Epub ahead of print]

PMID:
32035235
7.

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

Soulie C, Santoro MM, Storto A, Abdi B, Charpentier C, Armenia D, Jary A, Forbici F, Bertoli A, Gennari W, Andreoni M, Mussini C, Antinori A, Perno CF, Calvez V, Ceccherini-Silberstein F, Descamps D, Marcelin AG.

J Antimicrob Chemother. 2020 Apr 1;75(4):1026-1030. doi: 10.1093/jac/dkz553.

PMID:
31976534
8.

Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

Tzou PL, Descamps D, Rhee SY, Raugi DN, Charpentier C, Taveira N, Smith RA, Soriano V, de Mendoza C, Holmes SP, Gottlieb GS, Shafer RW.

J Infect Dis. 2020 Jan 22. pii: jiaa026. doi: 10.1093/infdis/jiaa026. [Epub ahead of print]

PMID:
31965175
9.

Editorial: Innovative Therapeutic and Vaccine Approaches Against Respiratory Pathogens.

Calzas C, Descamps D, Chignard M, Chevalier C.

Front Immunol. 2019 Dec 17;10:2960. doi: 10.3389/fimmu.2019.02960. eCollection 2019. No abstract available.

10.

Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity.

Le Hingrat Q, Visseaux B, Bertine M, Chauveau L, Schwartz O, Collin F, Damond F, Matheron S, Descamps D, Charpentier C.

J Virol. 2020 Mar 17;94(7). pii: e01504-19. doi: 10.1128/JVI.01504-19. Print 2020 Mar 17.

PMID:
31915276
11.

Exploration of the effects of sequence variations between HIV-1 and HIV-2 proteases on their three-dimensional structures.

Triki D, Kermarrec M, Visseaux B, Descamps D, Flatters D, Camproux AC, Regad L.

J Biomol Struct Dyn. 2019 Dec 27:1-13. doi: 10.1080/07391102.2019.1704877. [Epub ahead of print]

PMID:
31830870
12.

Physiopathology of HIV-2 infection.

Visseaux B, Le Hingrat Q, Damond F, Charpentier C, Descamps D.

Virologie (Montrouge). 2019 Oct 1;23(5):277-291. doi: 10.1684/vir.2019.0789.

PMID:
31826849
13.

Respiratory syncytial virus tropism for olfactory sensory neurons in mice.

Bryche B, Frétaud M, Saint-Albin Deliot A, Galloux M, Sedano L, Langevin C, Descamps D, Rameix-Welti MA, Eléouët JF, Le Goffic R, Meunier N.

J Neurochem. 2019 Dec 7:e14936. doi: 10.1111/jnc.14936. [Epub ahead of print]

PMID:
31811775
14.

Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube.

San C, Lê MP, Matheron S, Mourvillier B, Caseris M, Timsit JF, Wolff M, Yazdanpanah Y, Descamps D, Peytavin G.

Med Mal Infect. 2019 Nov 10. pii: S0399-077X(19)31062-5. doi: 10.1016/j.medmal.2019.10.010. [Epub ahead of print] Review.

PMID:
31722864
15.

Was Zika introduced to Brazil by participants at the 2013 Beach Soccer World Cup held in Tahiti: A phylogeographical analysis.

Le Hingrat Q, Perrier M, Charpentier C, Jacquot A, Houhou-Fidouh N, Descamps D, Visseaux B.

Travel Med Infect Dis. 2019 Nov 5:101512. doi: 10.1016/j.tmaid.2019.101512. [Epub ahead of print]

PMID:
31704483
16.

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, De Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, Chaix ML; AC43 ANRS Resistance Group .

J Antimicrob Chemother. 2020 Jan 1;75(1):183-193. doi: 10.1093/jac/dkz404.

PMID:
31641777
17.

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Tzou PL, Rhee SY, Descamps D, Clutter DS, Hare B, Mor O, Grude M, Parkin N, Jordan MR, Bertagnolio S, Schapiro JM, Harrigan PR, Geretti AM, Marcelin AG, Shafer RW; WHO HIVResNet Working Groups.

J Antimicrob Chemother. 2020 Jan 1;75(1):170-182. doi: 10.1093/jac/dkz417.

PMID:
31617907
18.

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017.

Wirden M, De Oliveira F, Bouvier-Alias M, Lambert-Niclot S, Chaix ML, Raymond S, Si-Mohammed A, Alloui C, André-Garnier E, Bellecave P, Malve B, Mirand A, Pallier C, Poveda JD, Rabenja T, Schneider V, Signori-Schmuck A, Stefic K, Calvez V, Descamps D, Plantier JC, Marcelin AG, Visseaux B, On Behalf Of The French National Agency For Research On Aids And Viral Hepatitis Anrs Ac Study Group.

Euro Surveill. 2019 Sep;24(39). doi: 10.2807/1560-7917.ES.2019.24.39.1800658.

19.

Cascaded harmonic generation from a fiber laser: a milliwatt XUV source.

Comby A, Descamps D, Beauvarlet S, Gonzalez A, Guichard F, Petit S, Zaouter Y, Mairesse Y.

Opt Express. 2019 Jul 22;27(15):20383-20396. doi: 10.1364/OE.27.020383.

PMID:
31510133
20.

Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.

Néant N, Solas C, Bouazza N, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Gattacceca F.

J Antimicrob Chemother. 2019 Jul 1;74(7):1992-2002. doi: 10.1093/jac/dkz141.

PMID:
31225609
21.

Piloting a surveillance system for HIV drug resistance in the European Union.

van de Laar MJ, Bosman A, Pharris A, Andersson E, Assoumou L, Ay E, Bannert N, Bartmeyer B, Brady M, Chaix ML, Descamps D, Dauwe K, Fonager J, Hauser A, Lunar M, Mezei M, Neary M, Poljak M, van Sighem A, Verhofstede C, Amato-Gauci AJ, Broberg EK.

Euro Surveill. 2019 May;24(19). doi: 10.2807/1560-7917.ES.2019.24.19.1800390.

22.

Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey.

Ferré VM, Ekouevi DK, Gbeasor-Komlanvi FA, Collin G, Le Hingrat Q, Tchounga B, Salou M, Descamps D, Charpentier C, Dagnra AC.

Clin Microbiol Infect. 2019 Dec;25(12):1560.e1-1560.e7. doi: 10.1016/j.cmi.2019.04.015. Epub 2019 Apr 30.

PMID:
31051265
23.

New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.

Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E.

J Antimicrob Chemother. 2019 Jul 1;74(7):2019-2023. doi: 10.1093/jac/dkz151.

PMID:
31050739
24.

Optics-less focusing of XUV high-order harmonics.

Quintard L, Strelkov V, Vabek J, Hort O, Dubrouil A, Descamps D, Burgy F, Péjot C, Mével E, Catoire F, Constant E.

Sci Adv. 2019 Apr 5;5(4):eaau7175. doi: 10.1126/sciadv.aau7175. eCollection 2019 Apr.

25.

New insights are game-changers in HIV-2 disease management.

Le Hingrat Q, Charpentier C, Ghosn J, Thiébaut R, Peytavin G, Descamps D, Matheron S.

Lancet HIV. 2019 Apr;6(4):e214. doi: 10.1016/S2352-3018(19)30088-8. No abstract available.

PMID:
30942186
26.

Wavelength scaling of terahertz pulse energies delivered by two-color air plasmas.

Nguyen A, Kaltenecker KJ, Delagnes JC, Zhou B, Cormier E, Fedorov N, Bouillaud R, Descamps D, Thiele I, Skupin S, Jepsen PU, Bergé L.

Opt Lett. 2019 Mar 15;44(6):1488-1491. doi: 10.1364/OL.44.001488.

PMID:
30874683
27.

Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy.

Brunet-Possenti F, Charpentier C, Bouhnik Y, Deschamps L, Descamps D, Moins-Teisserenc H, Descamps V.

JAMA Dermatol. 2019 May 1;155(5):629-631. doi: 10.1001/jamadermatol.2018.5528. No abstract available.

PMID:
30865238
28.

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen.

Sesterhenn F, Galloux M, Vollers SS, Csepregi L, Yang C, Descamps D, Bonet J, Friedensohn S, Gainza P, Corthésy P, Chen M, Rosset S, Rameix-Welti MA, Éléouët JF, Reddy ST, Graham BS, Riffault S, Correia BE.

PLoS Biol. 2019 Feb 21;17(2):e3000164. doi: 10.1371/journal.pbio.3000164. eCollection 2019 Feb.

29.

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.

Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P; ANRS AC43 Resistance Group.

J Antimicrob Chemother. 2019 May 1;74(5):1368-1375. doi: 10.1093/jac/dkz021.

PMID:
30789205
30.

HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.

Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C.

J Antimicrob Chemother. 2019 Jun 1;74(6):1679-1692. doi: 10.1093/jac/dkz043.

PMID:
30768160
31.

Ultrafast electronic relaxations from the S3 state of pyrene.

Noble JA, Aupetit C, Descamps D, Petit S, Simon A, Mascetti J, Ben Amor N, Blanchet V.

Phys Chem Chem Phys. 2019 Jul 3;21(26):14111-14125. doi: 10.1039/c8cp06895j.

PMID:
30758357
32.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D; ANRS AC-43 Resistance Study Group.

J Antimicrob Chemother. 2019 May 1;74(5):1417-1424. doi: 10.1093/jac/dkz011.

PMID:
30753724
33.

Metabolic syndrome and endocrine status in HIV-infected transwomen.

Pommier JD, Laouénan C, Michard F, Papot E, Urios P, Boutten A, Peytavin G, Ghander C, Lariven S, Castanedo G, Moho D, Landman R, Phung B, Perez E, Julia Z, Descamps D, Roland-Nicaise P, Le Gac S, Yazdanpanah Y, Guibourdenche J, Yeni P.

AIDS. 2019 Apr 1;33(5):855-865. doi: 10.1097/QAD.0000000000002152.

PMID:
30664006
34.

Characterizing the structural variability of HIV-2 protease upon the binding of diverse ligands using a structural alphabet approach.

Triki D, Fartek S, Visseaux B, Descamps D, Camproux AC, Regad L.

J Biomol Struct Dyn. 2019 Oct;37(17):4658-4670. doi: 10.1080/07391102.2018.1562985. Epub 2019 Feb 1.

PMID:
30593258
35.

Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification.

Désiré N, Cerutti L, Le Hingrat Q, Perrier M, Emler S, Calvez V, Descamps D, Marcelin AG, Hué S, Visseaux B.

Retrovirology. 2018 Dec 22;15(1):80. doi: 10.1186/s12977-018-0461-y.

36.

Real-time determination of enantiomeric and isomeric content using photoelectron elliptical dichroism.

Comby A, Bloch E, Bond CMM, Descamps D, Miles J, Petit S, Rozen S, Greenwood JB, Blanchet V, Mairesse Y.

Nat Commun. 2018 Dec 6;9(1):5212. doi: 10.1038/s41467-018-07609-9.

37.

Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey.

Ferré VM, Gbeasor-Komlanvi FA, Collin G, Dagnra AC, Le Hingrat Q, Jaquet A, Salou M, Descamps D, Charpentier C, Ekouevi DK.

Clin Infect Dis. 2019 Aug 30;69(6):1019-1026. doi: 10.1093/cid/ciy1012.

PMID:
30520971
38.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y; LAMIDOL Study Group.

J Antimicrob Chemother. 2019 Mar 1;74(3):739-745. doi: 10.1093/jac/dky467.

PMID:
30476165
39.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.

Soulie C, Santoro MM, Charpentier C, Storto A, Paraskevis D, Di Carlo D, Gennari W, Sterrantino G, Zazzi M, Perno CF, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG.

J Antimicrob Chemother. 2019 Mar 1;74(3):614-617. doi: 10.1093/jac/dky464.

PMID:
30476106
40.

A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.

Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO5 HIV-2 Cohort.

Clin Infect Dis. 2019 Aug 1;69(4):657-667. doi: 10.1093/cid/ciy940.

PMID:
30383215
41.

HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man.

Cazals N, Le Hingrat Q, Abraham B, Da Silva P, Guindre L, Goffart S, Damond F, Visseaux B, Charpentier C, Ranger-Rogez S, Descamps D.

Open Forum Infect Dis. 2018 Sep 11;5(10):ofy223. doi: 10.1093/ofid/ofy223. eCollection 2018 Oct.

42.

Multiphoton photoelectron circular dichroism of limonene with independent polarization state control of the bound-bound and bound-continuum transitions.

Beaulieu S, Comby A, Descamps D, Petit S, Légaré F, Fabre B, Blanchet V, Mairesse Y.

J Chem Phys. 2018 Oct 7;149(13):134301. doi: 10.1063/1.5042533.

PMID:
30292203
43.

Paradigms of Lung Microbiota Functions in Health and Disease, Particularly, in Asthma.

Mathieu E, Escribano-Vazquez U, Descamps D, Cherbuy C, Langella P, Riffault S, Remot A, Thomas M.

Front Physiol. 2018 Aug 21;9:1168. doi: 10.3389/fphys.2018.01168. eCollection 2018. Review.

44.

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T).

Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wirden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S.

Chem Biol Drug Des. 2019 Jan;93(1):50-59. doi: 10.1111/cbdd.13378. Epub 2018 Nov 27.

PMID:
30103267
45.

Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.

Alessandri-Gradt E, Charpentier C, Leoz M, Mourez T, Descamps D, Plantier JC.

J Antimicrob Chemother. 2018 Oct 1;73(10):2716-2720. doi: 10.1093/jac/dky271.

PMID:
30032194
46.
47.

Porcine Alveolar Macrophage-like cells are pro-inflammatory Pulmonary Intravascular Macrophages that produce large titers of Porcine Reproductive and Respiratory Syndrome Virus.

Bordet E, Maisonnasse P, Renson P, Bouguyon E, Crisci E, Tiret M, Descamps D, Bernelin-Cottet C, Urien C, Lefèvre F, Jouneau L, Bourry O, Leplat JJ, Schwartz-Cornil I, Bertho N.

Sci Rep. 2018 Jul 5;8(1):10172. doi: 10.1038/s41598-018-28234-y.

48.

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.

Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, Lambert-Niclot S, Desire N, Grude M, Morand-Joubert L, Flandre P, Katlama C, Descamps D, Calvez V, Todesco E, Marcelin AG.

J Antimicrob Chemother. 2018 Sep 1;73(9):2485-2492. doi: 10.1093/jac/dky198.

PMID:
29873733
49.

Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.

Perrier M, Désiré N, Storto A, Todesco E, Rodriguez C, Bertine M, Le Hingrat Q, Visseaux B, Calvez V, Descamps D, Marcelin AG, Charpentier C.

PLoS One. 2018 Jun 1;13(6):e0198334. doi: 10.1371/journal.pone.0198334. eCollection 2018.

50.

Reply to Das and Berkhout, "How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir".

Malet I, Subra F, Richetta C, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O.

mBio. 2018 May 29;9(3). pii: e00623-18. doi: 10.1128/mBio.00623-18. No abstract available.

Supplemental Content

Loading ...
Support Center